Announcements Trials
Browse Landscape

Phase

Phase 2 24Phase 1/2 2Phase NA 1Phase EARLY_PHASE1 1Phase 3 1Phase 1 1

Status

Suspended 1Recruiting 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Pancreatic Neoplasms 1Breast Neoplasms 1

Interventions

Cyclophosphamide 250Radiotherapy 172pembrolizumab 155Carboplatin 147Gemcitabine 139Nivolumab 135Paclitaxel 129Dexamethasone 119Cisplatin 118fludarabine 115Rituximab 104Lenalidomide 103Bevacizumab 99Docetaxel 97Capecitabine 97fludarabine phosphate 92Temozolomide 89Cytarabine 89Oxaliplatin 87Etoposide 82Filgrastim 77Irinotecan 73Doxorubicin 73venetoclax 70Peripheral Blood Stem Cell Transplantation 68Fluorouracil 68Radiosurgery 66Melphalan 66Everolimus 66Bortezomib 66

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × OTHER × zimberelimab × Clear all
NCT05419479 2026-02-24

Switch Maintenance in Pancreatic

Dana-Farber Cancer Institute

Phase 1/2 Suspended
46 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT06238921 2025-12-05

Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases

H. Lee Moffitt Cancer Center and Research Institute

Phase 1/2 Recruiting
31 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡